-3%

est. 2Y upside i

HealthcareSeries A

Meet Aniva, your personal health concierge. 100+ lab tests & personalized action plan with just one blood draw. Join now and start building the healthiest decade of your life.

Rank

#3633

Sector

Digital Health

Est. Liquidity

~8Y

Data Quality

Data: Low

Aniva is an extremely high-risk equity position: founded in 2025 with only 2 employees, no disclosed revenue, and no known valuation, the probability-weighted expected upside is approximately -3%, meaning failure odds outweigh bull-case gains for common stockholders over a 2-year window.

Last updated: May 5, 2026

Bull (15%)+200%

Aniva closes a Series A at ~$15-20M valuation within 18-24 months, implying a 4-5x step-up from an estimated $3-5M seed post-money. After ~20% dilution from new investors, employee common stock reflects ~200% paper upside — but remains fully illiquid with no secondary market.

Base (40%)+20%

Aniva raises a bridge or modest seed extension at a 1.3-1.5x step-up, achieving early customer traction on the €199/year plan but missing aggressive growth targets. Employee equity appreciates ~20% on paper over 2 years with zero secondary liquidity and continued dilution risk ahead.

Bear (45%)-90%

With only 2 employees, no disclosed revenue, and an undisclosed funding amount, Aniva fails to secure follow-on capital within 18 months and exhausts runway. Employee common stock is effectively wiped out, returning approximately -90% of grant value in a wind-down or distressed asset sale.

Est. time to liquidity~8.0 years

Preference Stack Risk

moderate

Funding Intensity

0%

Both total funding and current valuation are undisclosed; seed-stage rounds typically carry 1x non-participating liquidation preferences, but without dollar amounts the true preference overhang cannot be quantified.

Dilution Risk

high

As a 2-employee pre-revenue company, Aniva will require multiple future rounds (Series A, B, and likely C) before any exit — each round typically dilutes common stock 15-25%, compounding to 50-70% total dilution before a liquidity event.

Secondary Liquidity

none

At seed stage with 2 employees and no revenue, there is zero secondary market for Aniva equity; any shares granted are locked until a liquidity event realistically 7-10 years away.

Questions to Ask at the Interview

Strategic questions based on Aniva's data — designed to show you've done your homework.

  • 1

    “What is Aniva's durable data moat versus Function Health or Everlywell — specifically, how does the AI personalization layer compound switching costs as biomarker history accumulates?”

  • 2

    “What is the current monthly active subscriber count and 12-month retention rate for the €199/year plan, and what CAC are you running in your first acquisition channels?”

  • 3

    “What is the post-money valuation and fully diluted cap table from the Tetrad.vc round, and what liquidation preferences and anti-dilution provisions do investors hold?”

Community

Valuation Sentiment

Our model estimates -3% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.